4-cyano-N-{(2S)-2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]propyl}-N-pyridin-2-ylbenzamide hydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-cyano-N-{(2S)-2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]propyl}-N-pyridin-2-ylbenzamide hydrochloride
• 英文别名: 4-cyano-N-[(2S)-2-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-N-pyridin-2-ylbenzamide;hydrochloride
• 化学式: C₂₈H₂₉N₅O₃*ClH
• 分子量: 520.031
• InChiKey: GXYZREDEYDFJPT-BOXHHOBZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.0
• 重原子数：
  37
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  81.9
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  1-(2,3-二氢-1,4-苯并二烷-5-基)哌嗪盐酸盐 在 potassium carbonate 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 78.0h， 生成 4-cyano-N-{(2S)-2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]propyl}-N-pyridin-2-ylbenzamide hydrochloride
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Benzodioxanylpiperazine Derivatives as Potent Serotonin 5-HT_1A Antagonists:  The Discovery of Lecozotan

  摘要：

  A series of benzodioxanylpiperazine derivatives possessing a 4-aryl amide substituent was prepared and evaluated for 5-HT1A affinity and functional antagonist activity in vitro and in vivo. All of the compounds in this series possessed high affinity for the human 5-HT1A receptor and many displayed potent antagonist activity in vitro and varying degrees of intrinsic activity in vivo. Compound 11c (Lecozotan) was selected for further development and is currently in clinical trials.

  DOI：

  10.1021/jm049493z

文献信息

• PHARMACEUTICAL DOSAGE FORMS AND COMPOSITIONS OF 5-HT1A RECEPTOR ANTAGONISTS
  申请人：Wyeth

  公开号：EP1730139A2

  公开（公告）日：2006-12-13
• PHARMACEUTICAL DOSAGE FORMS AND COMPOSITIONS COMPRISING LECOZTAN
  申请人：Wyeth

  公开号：EP1928863A2

  公开（公告）日：2008-06-11
• Pharmaceutical dosage forms and compositions
  申请人：Ghosh Krishnendu

  公开号：US20050215561A1

  公开（公告）日：2005-09-29

  This invention relates to, for example, novel formulations and methods for the delivery of 4-cyano-N-(2R)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5yl)-piperazin-1-yl]-propyl}-N-pyridin-2-yl-benzamide, pharmaceutically acceptable salts thereof, structurally related compounds and/or metabolites; as well as to use of these formulations and methods for treating disease.
• [EN] PHARMACEUTICAL DOSAGE FORMS AND COMPOSITIONS<br/>[FR] FORMES POSOLOGIQUES PHARMACEUTIQUES ET COMPOSITIONS
  申请人：WYETH CORP

  公开号：WO2005092307A2

  公开（公告）日：2005-10-06

  This invention relates to, for example, novel formulations and methods for the delivery of 4-­cyano-N- (2R)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5 yl)-piperazin-l-yl]-propyl}-N-pyridin-2-yl­benzamide, pharmaceutically acceptable salts thereof, structurally related compounds and/or metabolites; as well as to use of these formulations and methods for treating disease.
• [EN] PHARMACEUTICAL DOSAGE FORMS AND COMPOSITIONS<br/>[FR] FORMES DOSIFIEES PHARMACEUTIQUES ET COMPOSITIONS ASSOCIEES
  申请人：WYETH CORP

  公开号：WO2007030589A2

  公开（公告）日：2007-03-15

  [EN] The invention relates to, for example, novel formulations and methods for the delivery of 4-cyano-N-(2R)-2-[4-(2,3-dihydro-benzo[l ,4]dioxin-5-yl)-piperazin-l -yl]-propyl}-N- pyridin-2-yl-benzamide, pharmaceutically acceptable salts thereof, structurally related compounds and/or metabolites; as well as to use of these formulations and methods for treating disease.
  [FR] L'invention concerne, par exemple de nouvelles formulations et de nouvelles méthodes pour distribuer du 4-cyano-N-(2R)-2-[4-(2,3-dihydro-benzo[l,4]dioxin-5-yl)-piperazin-l -yl]-propyl}-N- pyridin-2-yl-benzamide, des sels pharmaceutiquement acceptables de celui-ci, des composés structurellement associés à celui-ci et/ou des métabolites structurellement associés à celui-ci. L'invention concerne également l'utilisation de ces formulations et de ces méthodes pour traiter des maladies.